Falk Hoffmann1, Gerd Glaeske. 1. Abteilung Gesundheitsökonomie, Gesundheitspolitik und Versorgungsforschung, ZeS, Universität Bremen, Bremen, Germany. hoffmann@zes.uni-bremen.de
Abstract
BACKGROUND: Cancer is in the focus of public and scientific interest as one of the leading causes of death, with an increasing case load due to demographic changes and rising treatment costs. Comparatively, little is known about health care utilization of cancer patients. METHODS: This article first gives an overview of health services research and claims data of German statutory health insurance funds. Second, claims data of the Gmünder ErsatzKasse (GEK) for a period of 3 months (10-12/2008) are used to analyze patterns of drug prescriptions by oncologists. RESULTS: A total of 1.98 million prescriptions were included. Based on all prescriptions, the proportion of compounded prescriptions is about 17 times higher for oncologists compared to other physicians (34.4% vs. 2.0%). Fur- thermore, the costs of these solutions prescribed by oncologists are higher (median: 397.68 Euros vs. 15.45 Euros). CONCLUSION: Health services research in oncology is urgently needed. Claims data of German health insurance funds offer a broad range of opportunities, especially when linked with other data. However, in the case of individually prepared solutions, claims data provide no further information on the drug.
BACKGROUND:Cancer is in the focus of public and scientific interest as one of the leading causes of death, with an increasing case load due to demographic changes and rising treatment costs. Comparatively, little is known about health care utilization of cancerpatients. METHODS: This article first gives an overview of health services research and claims data of German statutory health insurance funds. Second, claims data of the Gmünder ErsatzKasse (GEK) for a period of 3 months (10-12/2008) are used to analyze patterns of drug prescriptions by oncologists. RESULTS: A total of 1.98 million prescriptions were included. Based on all prescriptions, the proportion of compounded prescriptions is about 17 times higher for oncologists compared to other physicians (34.4% vs. 2.0%). Fur- thermore, the costs of these solutions prescribed by oncologists are higher (median: 397.68 Euros vs. 15.45 Euros). CONCLUSION: Health services research in oncology is urgently needed. Claims data of German health insurance funds offer a broad range of opportunities, especially when linked with other data. However, in the case of individually prepared solutions, claims data provide no further information on the drug.
Authors: F Hoffmann; F Andersohn; K Giersiepen; E Scharnetzky; E Garbe Journal: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Date: 2008-10 Impact factor: 1.513
Authors: J Ruof; J L Hülsemann; T Mittendorf; S Handelmann; J M von der Schulenburg; H Zeidler; S Merkesdal Journal: Ann Rheum Dis Date: 2003-06 Impact factor: 19.103